2279 related articles for article (PubMed ID: 18707092)
1. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
2. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Mitrasinovic PM
Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
[TBL] [Abstract][Full Text] [Related]
3. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Du QS; Wang SQ; Chou KC
Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
[TBL] [Abstract][Full Text] [Related]
4. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
5. Combining docking, scoring and molecular field analyses to probe influenza neuraminidase-ligand interactions.
Abu Hammad AM; Afifi FU; Taha MO
J Mol Graph Model; 2007 Sep; 26(2):443-56. PubMed ID: 17360207
[TBL] [Abstract][Full Text] [Related]
6. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.
Wei DQ; Du QS; Sun H; Chou KC
Biochem Biophys Res Commun; 2006 Jun; 344(3):1048-55. PubMed ID: 16647045
[TBL] [Abstract][Full Text] [Related]
7. Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV).
Hitaoka S; Matoba H; Harada M; Yoshida T; Tsuji D; Hirokawa T; Itoh K; Chuman H
J Chem Inf Model; 2011 Oct; 51(10):2706-16. PubMed ID: 21870866
[TBL] [Abstract][Full Text] [Related]
8. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
Park JW; Jo WH
Eur J Med Chem; 2010 Feb; 45(2):536-41. PubMed ID: 19914748
[TBL] [Abstract][Full Text] [Related]
9. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
Wang SQ; Du QS; Chou KC
Biochem Biophys Res Commun; 2007 Mar; 354(3):634-40. PubMed ID: 17266937
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase.
D'Ursi P; Chiappori F; Merelli I; Cozzi P; Rovida E; Milanesi L
Biochem Biophys Res Commun; 2009 Jun; 383(4):445-9. PubMed ID: 19371724
[TBL] [Abstract][Full Text] [Related]
11. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
12. Complexity in influenza virus targeted drug design: interaction with human sialidases.
Chavas LM; Kato R; Suzuki N; von Itzstein M; Mann MC; Thomson RJ; Dyason JC; McKimm-Breschkin J; Fusi P; Tringali C; Venerando B; Tettamanti G; Monti E; Wakatsuki S
J Med Chem; 2010 Apr; 53(7):2998-3002. PubMed ID: 20222714
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
[TBL] [Abstract][Full Text] [Related]
14. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Rungrotmongkol T; Frecer V; De-Eknamkul W; Hannongbua S; Miertus S
Antiviral Res; 2009 Apr; 82(1):51-8. PubMed ID: 19428595
[TBL] [Abstract][Full Text] [Related]
15. Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).
Du QS; Huang RB; Wei YT; Du LQ; Chou KC
J Comput Chem; 2008 Jan; 29(2):211-9. PubMed ID: 17559075
[TBL] [Abstract][Full Text] [Related]
16. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
17. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
18. 3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
Gao L; Zu M; Wu S; Liu AL; Du GH
Bioorg Med Chem Lett; 2011 Oct; 21(19):5964-70. PubMed ID: 21843936
[TBL] [Abstract][Full Text] [Related]
19. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
20. A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase.
Jedrzejas MJ; Singh S; Brouillette WJ; Air GM; Luo M
Proteins; 1995 Oct; 23(2):264-77. PubMed ID: 8592707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
